A novel domain antibody rationally designed against TNF-α using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides

Molecular Immunology

Volumn 44, Issue 9, 2007, Pages 2355-2361

  Qin, Weisong ^a   Feng, Jiannan ^b   Li, Yan ^b   Lin, Zhou ^b   Shen, Beifen ^b  

^a JINLING HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Domain antibody; Molecular modeling; TNF inhibitor; Variable region

Indexed keywords

NEUTRALIZING ANTIBODY; PEPTIDE; PROTEIN ATD5; PROTEIN TNFR1; PROTEIN TNFR2; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; CELL STRAIN L 929; COMPUTER AIDED DESIGN; CONTROLLED STUDY; CROHN DISEASE; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVATION; ESCHERICHIA COLI; HEAVY CHAIN; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IN VITRO STUDY; MOLECULAR MODEL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; STRUCTURAL PROTEOMICS; THEORETICAL STUDY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; CASPASES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME ACTIVATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

ESCHERICHIA COLI;

EID: 33846188996     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.10.016     Document Type: Article

References (35)

1. Berman J.E., Mellis S.J., Pollock R., Smith C.L., Suh H., Heinke B., Kowal C., Surti U., Chess L., Cantor C.R., et al. Content and organization of the human Ig VH locus: definition of three new VH families and linkage to the Ig CH locus. EMBO J. 7 (1988) 727-738
2. Beutler B., and Cerami A. The biology of cachetin/TNF. A primary mediator of the host response. Annu. Rev. Immunol. 7 (1989) 625-655
3. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., Hunziker W., Lesslauer W., and Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 3127-3131
4. Chirinos-Rojas C.L., Steward M.W., and Partidos C.D. A peptidomimetic antagonist of TNF-α mediated cytotoxicity identified from a phage-displayed random peptide library. J. Immunol. 161 (1998) 5621-5626
5. Chothia C., Lesk A.M., Tramontano A., Levitt M., Smith-Gill S.J., Air G., Sheriff S., Padlan E.A., Davies D., Tulip W.R., et al. Conformations of immunoglobulin hypervariable regions. Nature 342 (1989) 877-883
6. Chothia C., Lesk A.M., Gherardi E., Tomlinson I.M., Walter G., Marks J.D., Llewelyn M.B., and Winter G. Structural repertoire of the human VH segments. J. Mol. Biol. 227 (1992) 799-817
7. Dottorini T., Vaughan C.K., Walsh M.A., Losurdo P., and Sollazzo M. Crystal structure of a human VH: requirements for maintaining a monomeric fragment. Biochemistry 43 (2004) 622-628
8. Essen L., and Skerra A. The de novo design of an antibody combining site: crystallographic analysis of the VL domain confirms the structural model. J. Mol. Biol. 238 (1994) 226-244
9. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 19 (2001) 163-196
10. Feng J., Li Y., Zhang W., and Shen B. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design. Immunol. Lett. 98 (2005) 311-316
11. Genst E.D., Areskoug D., Decanniere K., Muyldermans S., and Andersson K. Kinetic and affinity predictions of a protein-protein interaction using multivariate experimental design. J. Biol. Chem. 277 (2002) 29897-29907
12. Holt L.J., Herring C., Jespers L.S., Woolven B.P., and Tomlinson I.M. Domain antibodies: proteins for therapy. Trends Biotechnol. 21 (2003) 484-490
13. Jones E.Y., Stuart D.I., and Walker N.P.C. Structure of tumor necrosis factor. Nature 338 (1989) 225-228
14. Kollias G., Douni E., Kassiotis G., and Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol. Rev. 169 (1999) 175-194
15. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., and Gottlieb A.B. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349 (2003) 2014-2022
16. Lewis M., Tartaglia L.A., Lee A., Bennett G.L., Rice G.C., Wong G.H.W., Chen E.Y., and Goeddel D.V. Cloning and expression and cross-linking analysis of the murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 2830-2834
17. Lipsky P., van der Heijde D.M., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1594-1602
18. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001) 487-501
19. Maini R., St. Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354 (1999) 1932-1939
20. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., and Blosch C.M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337 (1997) 141-147
21. Palladino M.A., Bahjat F.R., Theodorakis E.A., and Moldawer L.L. Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Discov. 2 (2003) 736-746
22. Qin W., Feng J., Zhang W., Li Y., and Shen B. A novel TNF-α antagonizing peptide-Fc fusion protein designed based on CDRs of TNF-α neutralizing monoclonal antibody. Biochem. Biophys. Res. Commun. 322 (2004) 1024-1028
23. Qin W., Feng J., Li Y., Lin Z., and Shen B. Fusion protein of CDR mimetic peptide with Fc inhibit TNF-α induced cytotoxicity. Mol. Immunol. 43 (2006) 660-666
24. Qin W., Feng J., Li Y., Lin Z., and Shen B. De novo design TNF-α antagonistic peptide based on the complex structure of TNF-α with its neutralizing monoclonal antibody Z12. J. Biotechnol. 125 (2006) 57-63
25. Schoichet B.K., Stroud R.M., Santi D.V., Kuntz I.D., and Perry K.M. Structure-based discovery of inhibitors of thymidylate synthase. Science 259 (1993) 1445-1450
26. Seckinger P., Isaaz S., and Dayer J.M. Purification and biologic characterization of a specific tumor necrosis factor-α inhibitor. J. Biol. Chem. 264 (1989) 11966-11973
27. Smyth M.J., and Johnstone R.W. Role of TNF in lymphocyte-mediated cytotoxicity. Microsc. Res. Technol. 50 (2000) 196-208
28. Steed P.M., Tansey M.G., Zalevsky J., Zhukovsky E.A., Desjarlais J.R., Szymkowski D.E., Abbott C., Carmichael D., Chan C., Cherry L., et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301 (2003) 1895-1898
29. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., and Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17 (1999) 331-367
30. Wedemayer G.J., Patten P.A., Wang L.H., Schultz P.G., and Stevens R.C. Structural insights into the evolution of an antibody combining site. Science 276 (1997) 1665-1669
31. Williams W.V., Moss D.A., Kieber-Emmons T., Cohen J.A., Myers J.N., Weiner D.B., and Greene M.I. Development of biologically active peptides based on antibody structure. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 5537-5541
32. Zaghouani H., Steinman R., Nonacs R., Shah H., Gerhard W., and Bona C. Presentation of a viral T cell epitope expressed in the CDR3 region of a self-immunoglobulin molecule. Science 259 (1993) 224-227
33. Zanetti M. Antigenized antibodies. Nature 355 (1992) 476-477
34. Zanetti M., Rossi F., Lanza P., Filaci G., Lee R.H., and Billetta R. Theoretical and practical aspects of antigenized antibodies. Immunol. Rev. 130 (1992) 125-145
35. Zhang W., Feng J., and Shen B. Identification of binding epitope of a monoclonal antibody (Z12) against human TNF-α using computer modeling and deletion mutant technique. Sci. China Ser. C 47 (2004) 167-174